Could a stem cell 'Education' help tame type 1 diabetes?

NCT ID NCT02624804

Completed Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested a new approach called Stem Cell Educator therapy in 13 adults with type 1 diabetes. The treatment involves taking a patient's own blood cells, processing them with stem cells, and returning them to the body. The main goal was to see if it is safe and feasible, with a focus on side effects and whether patients could complete the therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stem Cell Educator therapy (a process where a patient's own blood cells are treated outside the body and returned)
What this could lead to: If it works, this could point toward a way to help the body better manage type 1 diabetes without needing as much insulin.
What could go wrong: This is a very early, small pilot study with only 13 people. It mainly looks at safety, not whether it truly controls diabetes long-term. The therapy may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Hackensack University Medical Center - John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.